Journal
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Volume 4, Issue -, Pages 115-125Publisher
CELL PRESS
DOI: 10.1016/j.omtm.2016.12.007
Keywords
-
Categories
Funding
- Program for Intractable Diseases Research utilizing disease-specific iPSCs from Japan Agency for Medical Research and Development (AMED)
- Research Project for Practical Applications of Regenerative Medicine from AMED
- Daiichi Sankyo Foundation of Life Science
- grant for Core Center for iPS Cell Research of Research Center Network for Realization of Regenerative Medicine from AMED
Ask authors/readers for more resources
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal degenerative disorder of motor neurons (MNs). Embryonic stem cells (ESCs)/induced pluripotent stem cells (iPSCs) now help us to understand the pathomechanisms of ALS via disease modeling. Various methods to differentiate ESCs/iPSCs into MNs by the addition of signaling molecules have been reported. However, classical methods require multiple steps, and newer simple methods using the transduction of transcription factors run the risk of genomic integration of the vector genes. Heterogeneity of the expression levels of the transcription factors also remains an issue. Here we describe a novel approach for differentiating human and mouse ESCs/iPSCs into MNs using a single Sendai virus vector encoding three transcription factors, LIM/homeobox protein 3, neurogenin 2, and islet-1, which are integration free. This single-vectormethod, generatingHB9-positive cells on day 2 from human iPSCs, increases the ratio of MNs to neurons compared to the use of three separate Sendai virus vectors. In addition, the MNs derived via this method from iPSCs of ALS patients and model mice display disease phenotypes. This simple approach significantly reduces the efforts required to generate MNs, and it provides a useful tool for disease modeling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available